A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
Conditions: Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Neoplasms by Histologic Type; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Disorder Intervention: Biological: lisocabtagene maraleucel Sponsors: Juno Therapeutics, Inc.; Celgene Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 16, 2018 Category: Research Source Type: clinical trials
Phase I of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL
Conditions: Lymphoma; Lymphoma, Non-Hodgkin; Immune System Diseases; Immunoproliferative Disorders; Lymphatic Diseases; Lymphoproliferative Disorders; Neoplasms Interventions: Biological: ATLCAR.CD30.CCR4 cells; Biological: ALTCAR.CD30 cells; Drug: Bendamustine; Drug: Fludarabine Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC-CH University Cancer Research Fund Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 26, 2018 Category: Research Source Type: clinical trials
